NMS-E973, a novel synthetic inhibitor of Hsp90 with activity against multiple models of drug resistance to targeted agents, including intracranial metastases

Clinical Cancer Research

Volumn 19, Issue 13, 2013, Pages 3520-3532

  Fogliatto, Gianpaolo ^a   Gianellini, Laura ^a   Brasca, Maria G ^a   Casale, Elena ^a   Ballinari, Dario ^a   Ciomei, Marina ^a   Degrassi, Anna ^a   De Ponti, Anna ^a   Germani, Massimiliano ^b   Guanci, Marco ^a   Paolucci, Mauro ^a   Polucci, Paolo ^a   Russo, Micaela ^a   Sola, Francesco ^a   Valsasina, Barbara ^a   Visco, Carlo ^a   Zuccotto, Fabio ^a   Donati, Daniele ^a   Felder, Eduard ^a   Pesenti, Enrico ^a   Galvani, Arturo ^a   Mantegani, Sergio ^a   Isacchi, Antonella ^a   more..

^a Department of Biotechnology Nerviano Medical Sciences Srl ^*  (Italy)

^b Accelera Srl   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

5 [2,4 DIHYDROXY 6 (4 NITROPHENOXY)PHENYL] N (1 METHYLPIPERIDIN 4YL) ISOXAZOLE 3 CARBOXAMIDE; HEAT SHOCK PROTEIN 90 INHIBITOR; NMS E 973; UNCLASSIFIED DRUG; VEMURAFENIB; ANTINEOPLASTIC AGENT; HEAT SHOCK PROTEIN 90; ISOXAZOLE DERIVATIVE; NMS-E973; PROTEIN BINDING;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; BRAIN METASTASIS; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; CRYSTALLIZATION; DRUG BINDING; DRUG PROTEIN BINDING; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; MALE; MELANOMA; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; SINGLE DRUG DOSE; TISSUE DISTRIBUTION; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; ANTIBODY SPECIFICITY; BINDING SITE; BRAIN NEOPLASMS; CHEMISTRY; CONFORMATION; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; IC50; METABOLISM; METASTASIS; MOLECULAR DOCKING; PATHOLOGY; SECONDARY; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; BINDING SITES; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; HSP90 HEAT-SHOCK PROTEINS; HUMANS; INHIBITORY CONCENTRATION 50; ISOXAZOLES; MICE; MOLECULAR CONFORMATION; MOLECULAR DOCKING SIMULATION; NEOPLASM METASTASIS; ORGAN SPECIFICITY; PROTEIN BINDING; PROTEOLYSIS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84879857354     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-3512     Document Type: Article

References (50)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
2. Neckers L. Heat shock protein 90: the cancer chaperone. Heat Shock Proteins in Cancer 2007;231-52.
3. Jhaveri K, Taldone T, Modi S, Chiosis G. Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochim Biophys Acta 2012;1823:742-55.
4. Sydor JR, Normant E, Pien CS, Porter JR, Ge J, Grenier L, et al. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proc Natl Acad Sci U S A 2006;103:17408-13. (Pubitemid 44788982)
5. Wong K, Koczywas M, Goldman JW, Paschold EH, Horn L, Lufkin JM, et al. An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) as monotherapy in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2011;29(suppl):7500.
6. Neckers L, Workman P. Hsp90 Molecular chaperone inhibitors: are we there yet? Clin Cancer Res 2012;18:64-76.
7. Modi S, Stopeck A, Linden H, Solit D, Chandarlapaty S, Rosen N, et al. HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin Cancer Res 2011;17:5132-9.
8. Ying W, Du Z, Sun L, Foley KP, Proia DA, Blackman RK, et al. Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. Mol Cancer Ther 2012;11:475-84.
9. Sasaki T, Koivunen J, Ogino A, Yanagita M, Nikiforow S, Zheng W, et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res 2011;71:6051-60.
10. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF. Nature 2010;464:427-30.
11. Poulikakos PI, Rosen N. Mutant BRAF melanomas-dependence and resistance. Cancer Cell 2011;19:11-5.
12. Corcoran RB, Ebi H, Turke AB, Coffee EM, Nishino M, Cogdill AP, et al. EGFR-mediated reactivation of MAPK signaling contributes to insensitivity of BRAF-mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov 2012;2:227-35.
13. Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, et al. Unresponsiveness of colon cancer to BRAF (V600E) inhibition through feedback activation of EGFR. Nature 2012;483:100-3.
14. Costa DB, Kobayashi S, Pandya SS, Yeo WL, Shen Z, Tan W, et al.CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol 2011;29:e443-5.
15. Panaretou B, Prodromou C, Roe SM, O'Brien R, Ladbury JE, Piper PW, et al. ATP binding and hydrolysis are essential to the function of the Hsp90 molecular chaperone in vivo. EMBO J 1998;17:4829-36. (Pubitemid 28377183)
16. Leskovar A, Wegele H, Werbeck ND, Buchner J, Reinstein J. The ATPase cycle of the mitochondrial Hsp90 analog Trap1. J Biol Chem 2008;283:11677-88.
17. Dollins DE, Warren JJ, Immormino RM, Gewirth DT. Structures of GRP94-nucleotide complexes reveal mechanistic differences between the hsp90 chaperones. Mol Cell 2007;28:41-56. (Pubitemid 47531972)
18. Lundgren K, Zhang H, Brekken J, Huser N, Powell RE, Timple N, et al. BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. Mol Cancer Ther 2009;8:921.
19. Kuzmic P. Program DYNAFIT for the analysis of enzyme kinetic data: application to HIV proteinase. Anal Biochem 1996;237:260-73. (Pubitemid 26177089)
20. Karlsson R, Katsamba PS, Nordin H, Pol E, Myszka DG. Analyzing a kinetic titration series using affinity biosensors. Anal Biochem 2006;349:136-47. (Pubitemid 43129567)
21. Soncini C, Carpinelli P, Gianellini L, Fancelli D, Vianello P, Rusconi L, et al. PHA-680632, a novel Aurora kinase inhibitor with potent antitumoral activity. Clin Cancer Res 2006;12:4080-9. (Pubitemid 44078096)
22. Otwinowski Z, Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol 1997;276:307-26. (Pubitemid 27085611)
23. Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 2004;60(Pt 12 Pt 1):2126-32.
24. Murshudov GN, Vagin AA, Dodson EJ. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 1997;53(Pt 3):240-55. (Pubitemid 27235885)
25. Masters JR, Thomson JA, Daly-Burns B, Reid YA, Dirks WG, Packer P, et al. Short tandem repeat profiling provides an international reference standard for human cell lines. Proc Natl Acad Sci U S A 2001;98: 8012-7. (Pubitemid 32642678)
26. Lorenzi PL, Reinhold WC, Varma S, Hutchinson AA, Pommier Y, Chanock SJ, et al. DNA fingerprinting of the NCI-60 cell line panel. Mol Cancer Ther 2009;8:713-24.
27. Chou TC, Talalay P. Analysis of combined drug effects: a new look at a very old problem. Trends Pharmacol Sci 1983;4:450-4.
28. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A 1979;76:4350-4. (Pubitemid 9256559)
29. Simeoni M, Magni P, Cammia C, De Nicolao G, Croci V, Pesenti E, et al. Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents. Cancer Res 2004;64:1094-101. (Pubitemid 38176915)
30. Magni P, Germani M, De Nicolao G, Bianchini G, Simeoni M, Poggesi I, et al. A minimal model of tumor growth inhibition. IEEE Trans Biomed Eng 2008;55:2683-90.
31. McLaughlin M, Vandenbroeck K. The endoplasmic reticulum protein folding factory and its chaperones: new targets for drug discovery? Br J Pharmacol. 2011;162:328-45.
32. Ni M, Lee AS. ER chaperones in mammalian development and human diseases. FEBS Lett 2007;581:3641-51. (Pubitemid 47082516)
33. Altieri DC, Stein GS, Lian JB, Languino LR. TRAP-1, the mitochondrial Hsp90. Biochim Biophys Acta 2012;1823:767-73.
34. Eccles SA, Massey A, Raynaud FI, Sharp SY, Box G, Valenti M, et al. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res 2008;68:2850-60. (Pubitemid 351556284)
35. Doebele RC, Pilling AB, Aisner DL, Kutateladze TG, Le AT, Weickhardt AJ, et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 2012;18:1472-82.
36. Paraiso KH, Haarberg E, Wood E, Rebecca VW, Chen YA, Xiang Y, et al. The heat shock protein-90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms. Clin Cancer Res 2012;18:2502-14.
37. Sullivan RJ, Flaherty KT. BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and Resistance. J Skin Cancer 2011;2011:423239.
38. Yang H, Higgins B, Kolinsky K, Packman K, Bradley WD, Lee RJ, et al. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. Cancer Res 2012;72:779-89.
39. Jhaveri K, Modi S. HSP90 inhibitors for cancer therapy and overcoming drug resistance. Adv Pharmacol 2012;65:471-517.
40. Patel HJ, Modi S, Chiosis G, Taldone T. Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatment. Expert Opin Drug Discov 2011;6:559-87.
41. Soga S, Akinaga S, Shiotsu Y. Hsp90 inhibitors as anti-cancer agents, from basic discoveries to clinical development. Curr Pharm Des 2013;19:366-76.
42. Synta corporate presentation March 2013 [cited 2013 Apr 8]. Available from: http://www.syntapharma.com/Documents/Synta-Corporate-presentation.pdf.
43. Arteaga CL. Why is this effective HSP90 inhibitor not being developed in HER2 +breast cancer? Clin Cancer Res 2011;17:4919-21.
44. Fathi AT, Chabner BA. FLT3 inhibition as therapy in acute myeloid leukemia: a record of trials andtribulations.Oncologist 2011;16:1162-74.
45. Moore AS, Faisal A, Gonzalez de Castro D, Bavetsias V, Sun C, Atrash B, et al. Selective FLT3 inhibition of FLT3-ITDplus; acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns. Leukemia 2012;26:1462-70.
46. Deeken JF, Loscher W. The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin Cancer Res 2007;13:1663-74. (Pubitemid 46952931)
47. Eichler AF, Chung E, Kodack DP, Loeffler JS, Fukumura D, Jain RK. The biology of brain metastases - translation to new therapies. Nat Rev Clin Oncol 2011;8:344-56.
48. Chandarlapaty S, Sawai A, Ye Q, Scott A, Silinski M, Huang K, et al. SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity againstHERkinase-dependent cancers. Clin Cancer Res 2008;14:240-8. (Pubitemid 351378001)
49. Gaspar N, Sharp SY, Eccles SA, Gowan S, Popov S, Jones C, et al. Mechanistic evaluation of the novel HSP90 inhibitor NVP-AUY922 in adult and pediatric glioblastoma. Mol Cancer Ther 2010;9:1219-33.
50. Bao R, Lai CJ, Qu H, Wang D, Yin L, Zifcak B, et al. CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy. Clin Cancer Res 2009;15:4046-57.